Jasper Therapeutics
Jasper Therapeutics is a clinical-stage biotechnology company developing therapies to treat immune-mediated diseases; Briquilimab is an anti-KIT antibody.
- Public company
- Redwood City, CA, USUnited States
Jasper Therapeutics is a clinical-stage biotechnology company developing therapies to treat immune-mediated diseases; Briquilimab is an anti-KIT antibody.
jaspertx.comCrawled Nov 4, 2026
Dr. Adelman previously served as acting CMO of Jasper and held leadership roles in biopharma, including Chief Medical Officer positions at Aimmune Therapeutics, Alvine Pharmaceuticals, and Sunesis Pharmaceuticals.
Joshua A. Boyce is the Albert L. Sheffer Professor of Medicine at Harvard Medical School and Chief of the Division of Allergy and Clinical Immunology at Brigham and Women’s Hospital.
Dr. Shizuru is a professor of medicine and pediatrics at Stanford, specializing in blood and marrow transplantation and stem cell transplantation.
Rick Ruiz joined Jasper in 2024 as Vice President of Finance, bringing over 25 years of experience in accounting, financing, FP&A, and SEC reporting.
Jasper Therapeutics implements a 1-for-30 reverse stock split for its common shares, effective November 6, 2026. The clinical-stage biotech company specializes in therapies for immune-mediated diseases. The move adjusts the stock’s trading price and liquidity ahead of its Nasdaq listing as **JSPR**.
Nov 2026Jasper Therapeutics, IncNews article
Jasper Therapeutics completes enrollment for the first cohort of its Phase 2 renal study testing vensobafusp alfa (KP104) in patients with IgA nephropathy (IgAN). The company expects initial Stage 1 data for this treatment in IgAN by the end of 2026.
Oct 2026Jasper Therapeutics, IncNews article
Jasper Therapeutics has begun an offer to buy back all outstanding warrants for its common stock. The warrants were issued during the company’s underwritten public offering. Jasper Therapeutics develops therapies targeting immune-mediated diseases and operates as a clinical-stage biotechnology firm.
Oct 2026Jasper Therapeutics, IncNews article
Jasper Therapeutics appoints **Lisa Pitt** as Senior Vice President of Regulatory Affairs. The company strengthens its leadership in clinical and regulatory operations to advance its pipeline of cell and gene therapies. Pitt brings over two decades of experience in drug development and regulatory strategy to the biotech firm.
Sep 2026Jasper Therapeutics, IncNews article